TIDMRENE
RNS Number : 8054V
ReNeuron Group plc
10 April 2019
10 April 2019 AIM: RENE
ReNeuron Group plc
Director/PDMR Interest in Shares and Share Options
ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based
global leader in the development of cell-based therapeutics,
announces that the following share option grants were made today
under the Company's Long Term Incentive Plan (the "Plan"), its US
Incentive Stock Option Plan (the "US Plan") and its Non-Executive
Share Option Scheme to directors and Persons Discharging Managerial
Responsibilities (PDMRs) listed below.
The Plan allows the Company to grant tax-advantaged share
options under a Company Share Option Plan (the "CSOP Plan"), as
well as non-tax advantaged options. Where capacity exists for a
director/PDMR to be issued share options under the CSOP Plan, these
options are issued in parallel with non tax-advantaged options. The
figures per individual below, where applicable and except where
indicated, therefore comprise parallel grants of both CSOP Plan
share options and non tax-advantaged share options, the terms of
each grant ensuring that the exercise of one type of option reduces
the number exercisable under the other type of option on a share
for share basis. Individuals can therefore elect, subject to their
tax status, which specific option grant (CSOP or non tax-advantaged
options) they exercise.
The Plan also allows the Company to grant Incentive Stock
Options ("ISOs") under the US Plan, as well as a conditional right
to receive shares ("Conditional Rights") to employees in the US.
Where a US employee is issued ISOs under the US Plan, these options
are issued in parallel with Conditional Rights. The figures per
individual below, where applicable and except where indicated,
therefore comprise parallel grants of both ISOs and Conditional
Rights, the terms of each grant ensuring that the exercise of one
type of option or right reduces the number that vest under the
other type of option or right on a share for share basis. The
Conditional Rights are granted at nominal value and the ISOs have
an exercise price of 222 pence per share being the closing price of
the Company's shares on 09 April 2019.
Share options granted under the CSOP Plan are over shares up to
an aggregate market value of GBP30,000 (measured at the date of
grant) and with an exercise price of 222 pence per share, being the
closing mid-market price of the Company's shares on 09 April 2019.
Non tax-advantaged options are granted at nominal value.
Share options granted under the Plan and the US Plan (unless
otherwise stated) are exercisable from the third anniversary of the
award and are subject to the achievement of the following
performance conditions:
1) When the Company has signed out-licensing deal(s) for any of
its technologies or programmes which, together with other financial
resources, provides sufficient funding to allow the achievement of
clinical proof of concept data for the CTX and hRPC programmes, one
third of the options will vest.
2) When the Company's share price has doubled from the price at
the date of grant, one third of the options will vest.
3) When the sixth clinical trial of a ReNeuron cell therapy
completes, one third of the options will vest.
The Non-Executive Directors of the Company are remunerated
partly in cash and partly in the form of share options granted
under the Non-Executive Share Option Scheme. In order to remove as
far as possible any incentive element that might influence the
Non-Executive Directors' independence, share options are granted at
nominal value without performance conditions attaching and vest
over three years on a straight line basis.
Share option grants are deemed accepted by the option holder
unless expressly rejected within a period of 30 days from the date
of grant.
Name Title Date of Total shares Percentage
grant Number over which of issued
of share of share options shares
options options are held under option
(i) granted (post award)
Chief Medical 10 April
Richard Beckman(ii) Officer 2019 146,946 300,528 0.95%
---------------------- ----------- ---------- -------------- --------------
Non-executive 10 April
John Berriman Chairman 2019 6,000 54,252 0.17%
---------------------- ----------- ---------- -------------- --------------
Non-executive 10 April
Simon Cartmell Director 2019 6,000 54,252 0.17%
---------------------- ----------- ---------- -------------- --------------
Non-executive 10 April
Tim Corn Director 2019 6,000 47,452 0.15%
---------------------- ----------- ---------- -------------- --------------
10 April
Randolph Corteling Head of Research 2019 36,800 190,301 0.60%
---------------------- ----------- ---------- -------------- --------------
Non-executive 10 April
Claudia D'Augusta Director 2019 6,000 28,700 0.09%
---------------------- ----------- ---------- -------------- --------------
Non-executive 10 April
Chris Evans Director 2019 6,000 41,700 0.13%
---------------------- ----------- ---------- -------------- --------------
VP Development
& General Manager 10 April
Sharon Grimster - Wales 2019 70,000 318,821 1.01%
---------------------- ----------- ---------- -------------- --------------
John Hawkins 10 April
(iii) Financial Controller 2019 20,000 40,000 0.13%
---------------------- ----------- ---------- -------------- --------------
Chief Executive 10 April
Olav Hellebo Officer 2019 260,861 1,066,721 3.37%
---------------------- ----------- ---------- -------------- --------------
Chief Financial 10 April
Michael Hunt Officer 2019 103,785 556,002 1.76%
---------------------- ----------- ---------- -------------- --------------
Non-executive 10 April
Mike Owen Director 2019 6,000 31,700 0.10%
---------------------- ----------- ---------- -------------- --------------
Head of Regulatory 10 April
Shaun Stapleton Affairs 2019 58,000 275,897 0.87%
---------------------- ----------- ---------- -------------- --------------
10 April
Paula Thornton(iii) HR Director 2019 12,000 20,000 0.06%
---------------------- ----------- ---------- -------------- --------------
(i) The option grants are under the non-tax advantaged scheme
and (where capacity exists) the CSOP Plan (as detailed above) save
for (ii) below, which has been granted under the US Plan, and the
Non-Executive Directors' grants.
(ii) The grant to Dr Beckman includes the grant of ISOs under
the US Plan and Conditional Rights under The Plan. These options or
rights are exercisable subject to achievement of performance
conditions (1) to (3) above. The ISOs and Conditional Rights vest
from the second anniversary of grant onwards, the ISOs being
subject to an annual $100,000 limit based on the aggregate fair
value of shares subject to grant measured on the date of grant.
(iii) The grants to Mr Hawkins and Mrs Thornton are made under
The Plan and are exercisable subject to achievement of performance
conditions (1) and (3) above, with 50% of the options becoming
exercisable in each case.
The notifications set out below are provided in accordance with
the requirements of the EU Market Abuse Regulation and provide
further detail.
S
ENQUIRIES:
ReNeuron +44 (0)20 3819 8400
Olav Hellebø , Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan +44 (0) 20 7466 5000
Mark Court, Sophie Cowles, Tilly Abraham
Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
Nplus1 Singer Advisory LLP +44 (0) 20 7496 3000
Mark Taylor (Joint Broker)
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments, without the need for immunosuppressive
drugs. The Company's lead clinical-stage candidates are in
development for disability as a result of stroke and for the
blindness-causing disease, retinitis pigmentosa. ReNeuron is also
advancing its proprietary exosome technology platform as a
potential delivery system for drugs that would otherwise be unable
to reach their site of action. ReNeuron's shares are traded on the
London AIM market under the symbol RENE.L. For further information
visit www.reneuron.com.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
(Disclosure in relation to share options granted to Directors
and PDMRs)
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name John Berriman
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Non-Executive Chairman
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 6,000
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 10 April 2019
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Richard Beckman
--------------------------- ----------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------
a) Position/status Chief Medical Officer
--------------------------- ----------------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------- ----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name ReNeuron Group plc
--------------------------- ----------------------------------------------
b) LEI 2138003TU12CQ5TZO137
--------------------------- ----------------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
---------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
--------------------------- ----------------------------------------------
b) Nature of the transaction Grant of share options and conditional rights
--------------------------- ----------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 146,946
----------
--------------------------- ----------------------------------------------
d) Aggregated information N/A
--------------------------- ----------------------------------------------
e) Date of the transaction Granted 10 April 2019
--------------------------- ----------------------------------------------
f) Place of the transaction Outside a trading venue
--------------------------- ----------------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Simon Cartmell
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Non-Executive Director
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 6,000
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 10 April 2019
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Tim Corn
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Non-Executive Director
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 6,000
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 10 April 2019
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Randolph Corteling
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Head of Research
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 36,800
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 10 April 2019
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Claudia D'Augusta
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Non-Executive Director
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 6,000
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 10 April 2019
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Chris Evans
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Non-Executive Director
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 6,000
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 10 April 2019
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Sharon Grimster
----------------------------- ------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status VP Development & General Manager - Wales
----------------------------- ------------------------------------------
b) Initial notification Initial notification
/Amendment
----------------------------- ------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
----------------------------- ------------------------------------------
b) LEI 2138003TU12CQ5TZO137
----------------------------- ------------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
----------------------------- ------------------------------------------
b) Nature of the transaction Grant of share options
----------------------------- ------------------------------------------
Price(s) and volume(s) Price(s) Volume(s)
1p 70,000
----------
----------------------------- ------------------------------------------
d) Aggregated information N/A
----------------------------- ------------------------------------------
e) Date of the transaction Granted 10 April 2019
----------------------------- ------------------------------------------
f) Place of the transaction Outside a trading venue
----------------------------- ------------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name John Hawkins
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Financial Controller
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 20,000
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 10 April 2019
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Olav Hellebo
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Chief Executive Officer
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 260,861
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 10 April 2019
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Michael Hunt
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Chief Financial Officer
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 103,785
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 10 April 2019
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Mike Owen
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Non-Executive Director
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 6,000
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 10 April 2019
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Shaun Stapleton
------------------------------------ -----------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Head of Regulatory Affairs
------------------------------------ -----------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------ -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
------------------------------------ -----------------------------------
b) LEI 2138003TU12CQ5TZO137
------------------------------------ -----------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
------------------------------------ -----------------------------------
b) Nature of the transaction Grant of share options
------------------------------------ -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 58,000
----------
------------------------------------ -----------------------------------
d) Aggregated information N/A
------------------------------------ -----------------------------------
e) Date of the transaction Granted 10 April 2019
------------------------------------ -----------------------------------
f) Place of the transaction Outside a trading venue
------------------------------------ -----------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Paula Thornton
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status HR Director
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 12,000
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 10 April 2019
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHFMGMDFGFGLZM
(END) Dow Jones Newswires
April 10, 2019 09:37 ET (13:37 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024